Skip to main content
Clinical Trials/EUCTR2013-000315-24-FR
EUCTR2013-000315-24-FR
Active, not recruiting
Phase 1

Pharmaco-epidemiology of the treatment of the symptomatic pulmonary embolism among in-patients and 75 years old or more: prospective, multicentric PEAGE cohort

CHU SAINT-ETIENNE0 sites1,500 target enrollmentMay 16, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
CHU SAINT-ETIENNE
Enrollment
1500
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 16, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
CHU SAINT-ETIENNE

Eligibility Criteria

Inclusion Criteria

  • \- Age \> or \= to 75 years
  • \- Symptomatic pulmonary embolism confirmed by objective paraclinical
  • examination (CT or scintigraphy) with or without DVT associated
  • \- Date of PE within 3 days
  • \- Administration possible according to the recommended dosages of
  • anticoagulation whatever it is: UFH, LMWH (dalteparin, enoxaparin,
  • Fraxiparin, tinzaparin), fondaparinux, oral anticoagulants
  • (acenocoumarol, fluindione, warfarin) or oral anticoagulants direct according to AMM
  • (apixaban, dabigatran, edoxaban , rivaroxaban)
  • \- Indication of anticoagulant therapy for a period of at least 6 months

Exclusion Criteria

  • \- prescribed anticoagulant treatment on therapeutic dose over 72 hours
  • \- indication of a therapeutic dose anticoagulant treatment for another
  • \- Inability for whatever reasons, to prescribe at least one recommended
  • anticoagulant treatment to VTE\-PE treatment on heparin\-induced
  • thrombocytopenia requiring argatroban, lepirudin or danaparoid
  • \- bleeding
  • \- PE occurring despite well conducted anticoagulant treatment
  • \- Contraindications to recommended dose anticoagulant treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Spontaneous Urinary Stone Passage ENabled by Drugs
ISRCTN69423238niversity of Aberdeen (UK)1,200
Active, not recruiting
Phase 1
se of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine)and an alpha blocker(tamsulosin) - The SUSPEND trial - Symptomatic ureteric stone passage enabled by drugs (SUSPEND)se of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine) and an alpha blocker (tamsulosin).
EUCTR2010-019469-26-GBniversity of Aberdeen1,167
Active, not recruiting
Not Applicable
Sympthomatic and prophylactic treatment of drug induced oral dryness in elderly patients with high drug consumption. - Drug induced oral drynessOral dryness is a common problem with serious consquences, especially among elderly individuals. The most common reason for oral dryness is drug consumption. Research has shown that an individual with more than 5 prescribed drug is at risk for oral problems. Drug consumtion is increasing among elderly, mostly due to lack in cooperation in the health care system. Oral dryness have impact on quality of life with eating difficulties and an increased rsik for dental caries.
EUCTR2006-001468-21-SEKarolinska Institutet
Recruiting
Not Applicable
A Study of the Probability and Course of Jaw Corruption by Drugs: Observations in Patients with Lung Cancer and Bone Metastases in Multiple Facilitiesmedication-related osteonecrosis of the Jaw
JPRN-UMIN000038586ational Hospital Organization Kyoto Medical Center300
Completed
Phase 1
Efficacy and safety of Chinese herbal medicine (RCM-102) for treatment of seasonal allergic rhinitis (hayfever)seasonal allergic rhinitisInflammatory and Immune System - AllergiesRespiratory - Other respiratory disorders / diseasesAlternative and Complementary Medicine - Herbal remedies
ACTRN12612000209897Professor Charlie Xua104